Seeking Alpha

Quest Diagnostics (DGX) says U.S. regulators granted a de novo classification petition for the...

Quest Diagnostics (DGX) says U.S. regulators granted a de novo classification petition for the company's Stratify JCV Antibody Elisa testing service. The approval means doctors can now test for the risk of a potentially fatal brain infection caused by Tysabri, a multiple sclerosis treatment sold by Biogen Idec (BIIB) and Elan (ELN).
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector